FWBI News and Press, First Wave BioPharma Inc. From 09/22/23

2023-09-22 13:37:27 ET More on First Wave BioPharma Seeking Alpha’s Quant Rating on First Wave BioPharma Historical earnings data for First Wave BioPharma Financial information for First Wave BioPharma First Wave Biopharma announces exercise of warrant...

BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) dis...

2023-09-15 06:33:00 ET 3 Tips for Trading Penny Stocks With Low Volume Penny stocks, often priced below $5 per share, present a unique opportunity for investors looking to diversify their portfolios and tap into the potential of emerging companies. Trading penny stocks with low volu...

2023-09-14 13:39:25 ET Gainers: TradeUP Acquisition Corp. ( UPTD ) +62% . PFSweb ( PFSW ) +48% . Bruush Oral Care ( BRSH ) +33% . Nikola Corporation ( NKLA ) +25% . ENDRA Life Sciences ( NDRA ) +24% . First Wave BioPharma ( ...

2023-09-14 13:02:17 ET More on First Wave BioPharma Seeking Alpha’s Quant Rating on First Wave BioPharma Historical earnings data for First Wave BioPharma Financial information for First Wave BioPharma Sanofi in licensing pact with First Wave BioPharma...

BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal...

2023-09-14 10:05:32 ET DENVER, Colo., Sept 14, 2023 ( www.247marketnews.com)- News First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi – First Wave BioPharma (NASDAQ: FWBI) is trading at $0.88, up $0.45 (+103.33%), on 64...

2023-09-14 09:07:26 ET (24/7 MARKET NEWS) – First Wave BioPharma, Inc. (NASDAQ:FWBI) stated, this morning, that it signed an agreement to license Sanofi’s (NASDAQ:SNY) selective 5-HT4 receptor partial agonist, Capeserod, which First Wave will repurpose and develop for gastroin...

2023-09-14 06:46:02 ET More on Sanofi Sanofi: A 'Buy' Recommendation For Undervalued Growth Potential Sanofi ( SNY ) Q2 2023 Earnings Call Transcript Sanofi 2023 Q2 - Results - Earnings Call Presentation Sanofi: Powering Up And Offering Investors A Lot Of...

BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) dis...